Fasenra: Clinical Trials

5 trials of Fasenra, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 2 recruiting, 1 terminated. 5 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 35Completed 2, Recruiting 2, Terminated 1
Phase 21Completed 1

Follow Fasenra: new trials by email Literature Review of Fasenra trials Research Report on Fasenra

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment
Benralizumab - Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA)
Phase 3RecruitingAstraZeneca2302026-07-242026-11-13
A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases
Benralizumab - Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilia Syndrome (HES)
Phase 3RecruitingAstraZeneca142025-04-172026-10-28
STEP: Phase IIIb Study of Benralizumab to Step-down Maintenance Therapy in Patients With Severe Eosinophilic Asthma
Benralizumab - Severe Eosinophilic Asthma
Phase 3CompletedAstraZeneca5042024-02-282026-09-03
Efficacy and Safety of Benralizumab in Patients With Eosinophilic Gastritis and/or Gastroenteritis (The HUDSON GI Study)
Benralizumab, Placebo - Eosinophilic Gastritis, Eosinophilic Gastroenteritis
Phase 3TerminatedAstraZeneca122022-01-182025-07-14
Benralizumab for Eosinophilic Gastritis (BEGS)
Benralizumab, Placebo - Eosinophilic Gastritis or Gastroenteritis
Phase 2 / Phase 3CompletedChildren's Hospital Medical Center, Cincinnati262018-04-232022-02-03

Conditions studied

Churg-Strauss Syndrome (2)  ·  Eosinophilic enteropathy (2)  ·  Gastroenteritis (2)  ·  Asthma (1)  ·  Digestive System Diseases (1)  ·  Gastrointestinal Diseases (1)  ·  Hypereosinophilic Syndrome (1)  ·  Intestinal Diseases (1)  ·  Pulmonary Eosinophilia (1)  ·  Stomach Diseases (1)

Sponsors

AstraZeneca (4)  ·  Children's Hospital Medical Center, Cincinnati (1)

Countries

United States (4)  ·  Netherlands (3)  ·  Poland (3)  ·  Brazil (2)  ·  Canada (2)  ·  France (2)  ·  India (2)  ·  Israel (2)  ·  Italy (2)  ·  Turkey (Türkiye) (2)  ·  Argentina (1)  ·  Austria (1)  ·  Belgium (1)  ·  China (1)  ·  Japan (1)

Top investigators

HuaHao Shen, Professor (1)  ·  Marc E Rothenberg, MD, PhD (1)  ·  Marc E. Rothenberg, MD, PhD (1)  ·  Min Zhang, Professor (1)

Results publications

PMID 37336228

NIH funding

2023 (1)